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Abstract: BACKGROUND: Patients with mastocytosis often suffer from a variety of symptoms caused
by mast cell mediators where treatments remain difficult, showing various success rates. Omalizumab, a
monoclonal anti-IgE antibody, has been postulated to have a positive impact on mastocytosis-associated
symptoms such as flush, vertigo, gastrointestinal problems, or anaphylaxis. OBJECTIVE: To investigate
the efficacy and safety of omalizumab in systemic mastocytosis. METHODS: Patients with histologically
proven mastocytosis were investigated in a multicenter prospective double-blind placebo-controlled trial
to receive either omalizumab or placebo, dosed according to IgE and body weight. The primary endpoint
was change in the AFIRMM activity score after 6 months of treatment. Different laboratory parameters
were analyzed. RESULTS: Sixteen patients were analyzed: 7 to omalizumab and 9 to placebo (mean
age 47.7 ± 13.8 vs. 45.4 ± 8.8 years; 66.6 vs. 85.7% were female; mean disease duration 10.0 ± 5.1
vs. 4.5 ± 2.9 years, respectively). After 6 months the median AFIRMM score decreased 50% from
52.0 to 26.0 in the omalizumab group versus 104.0-102.0 in the placebo group (p = 0.286); however,
the difference was not significant (p = 0.941). Secondary endpoints, including the number of allergic
reactions, changes in major complaints, wheal-and-flare reaction due to mechanical irritation (Darier’s
sign), and frequency of the use of mastocytosis-specific drugs improved in the omalizumab group, but not
significantly. Adverse events like urticaria, bronchospasm, and anaphylactic shock showed no significant
difference between the groups. No severe adverse events occurred. Fc฀RI (Fc-epsilon receptor) expression
on basophils decreased after receiving omalizumab versus placebo. CONCLUSION: Omalizumab was
safe and showed a tendency to improve mastocytosis-related symptoms, in particular diarrhea, dizziness,
flush, and anaphylactic reactions, including the AFIRMM score and secondary endpoints; however, the
difference was not significant. Due to the small study size and difference at baseline between the study
groups, further studies are required to confirm our findings.
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Abstract
Background: Patients with mastocytosis often suffer from a 
variety of symptoms caused by mast cell mediators where 
treatments remain difficult, showing various success rates. 
Omalizumab, a monoclonal anti-IgE antibody, has been pos-
tulated to have a positive impact on mastocytosis-associat-
ed symptoms such as flush, vertigo, gastrointestinal prob-
lems, or anaphylaxis. Objective: To investigate the efficacy 
and safety of omalizumab in systemic mastocytosis. Meth-
ods: Patients with histologically proven mastocytosis were 
investigated in a multicenter prospective double-blind pla-
cebo-controlled trial to receive either omalizumab or place-
bo, dosed according to IgE and body weight. The primary 
endpoint was change in the AFIRMM activity score after 6 
months of treatment. Different laboratory parameters were 
analyzed. Results: Sixteen patients were analyzed: 7 to omal-
izumab and 9 to placebo (mean age 47.7 ± 13.8 vs. 45.4 ± 8.8 
years; 66.6 vs. 85.7% were female; mean disease duration 
10.0 ± 5.1 vs. 4.5 ± 2.9 years, respectively). After 6 months the 
median AFIRMM score decreased 50% from 52.0 to 26.0 in 
the omalizumab group versus 104.0–102.0 in the placebo 
group (p = 0.286); however, the difference was not signifi-
cant (p = 0.941). Secondary endpoints, including the number 
of allergic reactions, changes in major complaints, wheal-
and-flare reaction due to mechanical irritation (Darier’s sign), 
and frequency of the use of mastocytosis-specific drugs im-
proved in the omalizumab group, but not significantly. Ad-
verse events like urticaria, bronchospasm, and anaphylactic 
shock showed no significant difference between the groups. 










































































No severe adverse events occurred. FcεRI (Fc-epsilon recep-
tor) expression on basophils decreased after receiving omal-
izumab versus placebo. Conclusion: Omalizumab was safe 
and showed a tendency to improve mastocytosis-related 
symptoms, in particular diarrhea, dizziness, flush, and ana-
phylactic reactions, including the AFIRMM score and sec-
ondary endpoints; however, the difference was not signifi-
cant. Due to the small study size and difference at baseline 
between the study groups, further studies are required to 
confirm our findings. © 2020 S. Karger AG, Basel
Introduction
Mastocytosis is a rare disease with a prevalence of 
1/10,000 and often associated with symptoms that severe-
ly impair the quality of life of affected patients [1]. In ad-
dition, potentially life-threatening anaphylaxis occurs in 
as many as 30–49% of patients with mastocytosis repre-
senting an approximately 1,000-fold increase compared 
with the general population [2]. The disease is character-
ized by an accumulation of mastocytes in various organs, 
most commonly in the skin, bone marrow, and gastroin-
testinal tract [3–5]. Several forms can be distinguished, 
mainly cutaneous mastocytosis, where mast cell prolif-
eration is limited to the skin, and systemic forms with 
involvement of the bone marrow and other organs. 
Disease symptoms are caused by the release of mast 
cell mediators leading to nausea, fatigue, wheals, abdom-
inal cramps, diarrhea, or hypotension. These patients also 
have an increased frequency of anaphylactic/anaphylac-
toid reactions due to allergens such as Hymenoptera or 
nonspecific stimuli such as contrast media, local anes-
thetics, or analgesics which may be life-threatening [2, 6]. 
The trigger for mast cell activation may be allergic and 
therefore IgE dependent (food, medication, Hymenop-
tera venom, or aeroallergens). Mast cell activation can 
also be induced by IgE-independent drug reactions, alco-
hol, physical factors (trauma, friction, or extreme tem-
peratures), stress, venom, and acute or chronic infections. 
The discovery of the MRGPRX2 receptor on mast cells 
has shown that mast cells are capable of IgE-independent 
pathways of activation by different substances [7].
Symptoms of mastocytosis respond to treatment with 
antihistamines, glucocorticoids, or mast cell stabilizers, 
but often this treatment is insufficient or cannot be given 
permanently because of side effects. In patients with rap-
idly progressive systemic mastocytosis, aggressive masto-
cytosis, and mast cell leukemia, tyrosine kinase inhibitors 
are a therapeutic alternative and there are ongoing clini-
cal studies addressing the subject. But these therapies re-
veal a lot of side effects and are in general not a treatment 
option for patients with indolent systemic or cutaneous 
mastocytosis [8–10]. 
Several case reports and small observational studies 
suggest that omalizumab might decrease symptoms in-
cluding mastocytosis-associated anaphylaxis. Omali-
zumab has already been used successfully in long-term 
therapy of mastocytosis-associated anaphylaxis [11–17]. 
Omalizumab is a therapeutic monoclonal anti-IgE an-
tibody, approved for treatment of allergic asthma and 
chronic spontaneous urticaria. In asthma the onset of 
clinical efficacy of omalizumab is considered to take place 
about 4 months after the start of treatment. The suggest-
ed onset of action of omalizumab in other conditions 
such as urticaria has been described as within 8 weeks or 
1–2 weeks, respectively [18].
The aim of this study was to investigate in a prospec-
tive double-blind, randomized placebo-controlled multi-
center trial whether patients suffering from mastocytosis 
benefit from a 6-month course of omalizumab regarding 
symptoms and quality of life.
Methods
For further details, see the online supplementary Material (see 
www.karger.com/doi/10.1159/000504842 for all online suppl. 
 material,) [19, 20] (Fig. 1).
Results
Study Population
A total of 63 patients were pre-screened for this trial. Of 
these, 17 patients fulfilled the inclusion criteria and were 
enrolled at the 3 study centers: Zurich (ZH) (n = 9), Geneva 
(GE) (n = 4), and Berne (BE) (n = 4). Major reasons for the 
rejection to participate were fear of getting placebo and dif-
ficulties in attending the visits. Eleven patients suffered 
from indolent systemic mastocytosis, confirmed by bone 
marrow biopsy – 3 patients from cutaneous mastocytosis 
without sign of bone marrow involvement in the bone mar-
row biopsy. In 3 patients only a skin biopsy was done to 
confirm the diagnosis of cutaneous mastocytosis and a sys-
temic mastocytosis was not excluded. Two patients suffered 
from gastrointestinal mastocytosis with corresponding his-
tology (in some cases multiple instances) (Table 1).
The age distribution was the same in both groups 
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8.8 years in the placebo group; 66.6 vs. 85.7% were female, 
respectively). Similarly, a slight but not significant differ-
ence in the duration of the disease was seen in both groups 
(verum 10.0 ± 5.1 years vs. placebo 4.5 ± 2.9 years). There 
was no difference between the groups regarding disease 
manifestation (systemic vs. cutaneous mastocytosis) and 
tryptase level (Table 1). 
Randomization was based on study site and blog vise 
after the sequence of inclusion into the study. Unfortu-
nately, due to withdrawal of some patients after the ran-
domization an imbalance in the groups appeared.
Of the 17 patients included, 1 patient discontinued the 
study after the screening visit without stating reasons. 
Two other patients discontinued the study after random-
ization, but prior to any study medication, one because he 
did not want to risk placebo therapy because of his symp-
toms, and the other gave no reasons for discontinuation. 
After the start of the therapy, 2 other patients discontin-
ued the study without giving reasons. Twelve patients 
completed the study (Fig. 1).
Of the 14 patients receiving medication, 12 patients 
received 150 mg of the study medication (5 verum, 7 pla-
cebo) every 4 weeks and 2 patients received 300 mg (1 
verum, 1 placebo) every 4 weeks. 
Clinical Efficacy
The primary endpoint of the study was the change in 
the AFIRMM score between baseline at randomization 
XOLMA
Pre-screening (n = 63)
(ZH 50, GE 7, BE 6)
Included (n = 17)
(ZH 9, GE 4, BE 3)
n = 16
Randomization
Verum (n = 7)
Dropped out prior to
any treatment (n = 1) (ZH)
Dropped out prior to
any treatment (n = 1) (ZH)
Verum (n = 6)
Withdrew consent at V6 (n = 1) (GE)
ITT analysis: verum (n = 6)
PP analysis: verum (n = 5)
Did not participate (n = 46)
(ZH 41, GE 3, BE 2)
♦ Inclusion criteria not met (n = 16)
♦ participation rejected (n = 16)
♦ other reasons (n = 14) (ZH 9, GE 3, BE2)
Dropped out prior to randomization
(n = 1) (GE)
♦ (request of patient)
Placebo (n = 9)
Therapy + follow-up
Placebo (n = 8)
Withdrew consent at V3 (n = 1) (BE) 
Analysis
ITT analysis: placebo (n = 8)
PP analysis: placebo (n = 7)
Fig. 1. Flowchart of Methods: study enrol-
ment. Patient inclusion and exclusion flow 
diagram of the XOLMA trial. Analyzing 











































































(visit 1 [V1], month 0) and the end of treatment (visit 8 
[V8], month 6), to assess the efficacy of omalizumab in 
mastocytosis (Fig. 2a). 
Because of the low number of patients and the differ-
ence in the initial AFIRMM score between the placebo 
and verum groups, the relative difference with respect to 
V1 was also investigated in addition to the absolute dif-
ference in the AFIRMM score at V8.
Primary Endpoint 
For the intention-to-treat analysis, 16 patients were in-
















































































































Fig. 2. Change of mastocytosis symptoms. a AFIRMM score measured at all visits (V1 to V11) for the placebo group 
(n = 8) and the omalizumab group (n = 6) in the XOLMA trial. b Change of asthenia from visit 1 to 8. c Change of 
diarrhea from visit 1 to 8. d Change of gastrointestinal track complaints from visit 1 to 8. e Change of allergy/flush/
shock from visit 1 to 8. f Change of pruritus using the VAS from visit 1 to 8. Numerically, a difference was seen in 
mastocytosis symptoms; however, no significant difference was shown between omalizumab and placebo.
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in period) was 104.0 and 52.0 for the placebo (n = 9) and 
omalizumab groups (n = 7), respectively. Thus, the 
AFIRMM score was different between the placebo and 
omalizumab groups already at V1, though not signifi-
cantly (p = 0.077). At V8, the median AFIRMM score was 
102.0 and 26.0 for the placebo and omalizumab groups, 
respectively (p = 0.286). The AFIRMM score was thus re-
duced in both treatment groups, that is, by a median of 8 
score points in the placebo group and 6 score points in 
the omalizumab group (Table 2). 
The reduction was not statistically significantly differ-
ent in the treatment groups (p = 0.941). For the per pro-
tocol analysis, 12 patients were included (Table 3). The 
median AFIRMM score at V1 was 102.0 (n = 7) and 32.0 
(n = 5) for the placebo and omalizumab groups, respec-
tively. Thus, the AFIRMM score was significantly differ-
ent between the placebo and omalizumab groups already 
at V1 (p = 0.035). At V8, the median AFIRMM score was 
84.0 and 22.0 for the placebo (n = 7) and omalizumab 






































































































































































































score was thus reduced in both treatment groups, that is, 
by a median of 18 score points in the placebo group and 
12 score points in the omalizumab group. The amount of 
absolute reduction was not significantly different be-
tween the treatment groups (p = 0.912). The amount of 
relative reduction was also not significantly different be-
tween the treatment groups (p = 0.432); however, it was 
twice as large in the omalizumab as in the placebo group 
(Table 4). 
Secondary Endpoints
Secondary endpoints were the changes in the AFIRMM 
score at the end of the study, the number of allergic/ana-
phylactic reactions, changes in visual analog scale (VAS) 
for major complaints and itching, changes in wheal-and-
flare reaction, and the use of mastocytosis-specific drugs 
such as antihistamines or cromoglycates. Adverse events 
were also documented as safety endpoints, especially al-
lergic events such as urticaria, bronchospasm, anaphylac-
tic shock, and local reactions.
AFIRMM Score at Follow-Up
The absolute difference of the AFIRMM score between 
V1 (month 0, run-in period) and V9/V11 (month 7/12) 
was also computed and compared between the treatment 
groups. At V9, the median difference with respect to V1 
was increased by 16 score points for the placebo group, 
but decreased by 10 score points for the omalizumab 
Table 1. Demographics of the XOLMA trial
Patient Age at 
baseline, 
years
Gender Disease duration  













ZH-1 45 Male 10 2006 ISM 37.6 4
ZH-2 49 Male 6 2006 MIS 14.8 5
ZH-3 67 Female 4 2007 ISM 20.8 5
ZH-4 30 Female 3 2010 ISM 52.7 10
ZH-5 38 Male 2 2012 CM 23.7 24
ZH-6 53 Female 13 2006 CM 9.11 21
ZH-7 28 Female 8 2004 MIS 24.2 3
ZH-8 47 Female 18 2010 ISM 3.9 7
ZH-9 47 Female 7 2007 MIS 15.2 10
BE-1 36 Female 10 2003 ISM n.a. 102
BE-2 48 Female NA 2005 ISM 70.4 17
BE-3 57 Female 2 2012 ISM 32.2 NA
BE-4 52 Female 9 2014 ISM 30.4 5
GE-1 24 Female 1 2012 ISM 18.5 2
GE-2 63 Female 10 2003 CM 26.8 16
GE-3 36 Female 3 2010 ISM n.a. 5
GE-4 48 Male NA 2013 ISM 54.4 36
ISM, indolent systemic mastocytosis; CM, cutaneous mastocytosis (systemic mastocytosis excluded by bone marrow investigation); 
MIS, mastocytosis in the skin (cutaneous mastocytosis without bone marrow investigation).








Placebo 9 104.0 102.0 –8.0
Omalizumab 7 52.0 26.0 –6.0
All 16 0.941
Intention-to-treat analysis. V1, visit 1; V8, visit 8.
Table 2. Primary endpoint: difference in 
AFIRMM score between visit 1 and 8 in 
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group (p = 0.322). At V11, the median difference with re-
spect to V1 was decreased by 15 score points for both the 
placebo and the omalizumab group (p = 0.610).
Hermine et al. [20] assumed the mean AFIRMM score 
to be 117 in mastocytosis patients. This assumption was 
clearly not met, especially within the omalizumab group. As 
patients from the placebo and the omalizumab group were 
already different at V1, it cannot be ruled out that patients 
in the omalizumab group did not show a greater decrease 
in the affirm score because they started at a lower level.
Changes in VAS for Single Main Complaints
Three patients in the omalizumab group and 5 pa-
tients in the placebo group indicated asthenia as the main 
complaint. The course of the daily VAS score for asthe-
nia, which has been summarized per month, is shown in 
Figure 2b. Three patients in the omalizumab group and 
4 patients in the placebo group indicated diarrhea as the 
main complaint. The course of the daily VAS score, 
which has been summarized per month, is shown in Fig-
ure 2c. 
Four patients in the omalizumab group and 6 patients 
in the placebo group had a total of 6 and 7 complaints, 
respectively, from the gastrointestinal tract complaints of 
the AFIRMM score (aerophagia, nausea, epigastric pain, 
diarrhea, pseudo-occlusive syndrome) as main com-
plaints. The course of the daily VAS score, which has been 
summarized per month, is shown in Figure 2d. 
Three patients in the omalizumab group and 3 patients 
in the placebo group had a total of 5 and 3 complaints, 
respectively, from the allergy/flush complaints of the 
AFIRMM score (food allergy, drug allergy, olfactive in-
tolerance, anaphylaxis, flush) as main complaints. The 
course of the daily VAS score, which has been summated 
per month, is shown in Figure 2e. 
The changes for pruritus between V1 and V8 are 
shown in Figure 2f. The median slope was 3.6 in the pla-
cebo group and –3.1 in the omalizumab group. This dif-
ference was not statistically significant (p = 0.317).
Mast Cell-Specific Drugs
Since only 1 patient from the omalizumab group and 
4 patients from the placebo group used mast cell-specific 
drugs, a more detailed analysis was not possible due to the 
low number of patients.
Laboratory Markers
Of the IgE values determined at the beginning of the 
study, only in 1 patient was the total IgE > 100 kU/L. The 
tryptase values were between 3.94 and 70.4 µg/L. Trypt-
ase values remained unaltered for all patients for whom 
values were present, even after therapy with omalizum-
ab. 
FcεRI (Fc-epsilon receptor) expression showed a clear 
reduction in patients with omalizumab but was un-
changed in patients with placebo (Fig. 3). 







Placebo 7 102.0 84.0 –17.6
Omalizumab 5 32.0 22.0 –37.5
All 12 0.432
V1, visit 1; V8, visit 8.
Table 4. Primary endpoint: relative differ-
ence in percent AFIRMM score between 
visit 1 and 8 in the XOLMA population







Placebo 7 102.0 84.0 –18.0
Omalizumab 5 32.0 22.0 –12.0
All 12 0.912
Per protocol analysis.
Table 3. Primary endpoint: absolute 
 difference in AFIRMM score between visit 











































































Of a total of 100 occurring adverse events, 59 were found 
in the placebo group and 41 in the verum group. Ninety-
one events were rated as mild and 9 as moderate (7 in the 
placebo group and 2 in the verum group). No severe ad-
verse events occurred. An association with the study medi-
cation was considered as possible in a total of 9 patients (5 
in the placebo group and 4 in the omalizumab group); all 
these events were classified as mild. All adverse events are 
listed in detail in the online supplementary Appendix.
There were 4 adverse events like urticaria, broncho-
spasm, anaphylactic shock, and local reactions which are 
known to be associated with the study drug: 3 patients 
from the placebo group reported flushing and dizziness 
or muscle pain in the shoulder, flatulence or stomach 
cramps, and limb aches, respectively, after the injection 
of the study drug, and 1 patient in the omalizumab group 
reported headache and pain at the injection site after ad-
ministration of the study drug. There was no difference 
between the 2 groups (p = 0.702).
Discussion
To our knowledge, this is the first randomized, place-
bo-controlled study of omalizumab in mastocytosis. To 
date, only small open studies and case reports reported an 
effect of omalizumab in mastocytosis, especially for ana-
phylaxis [11–14]. Unfortunately, we were able to include 







































Fig. 3. a FcεRI expression (mean receptor 
density per cell) in patients treated with 
omalizumab measured at visits 1, 3, 7, and 
9 during the clinical trial. b FcεRI expres-
sion (mean receptor density per cell) in pa-
tients treated with placebo measured at vis-
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our study has more the ability to detect trends than to 
reach significant changes in the 2 groups due to the small 
sample size.
An improvement in the AFIRMM score between V1 
and V8 was seen as the primary endpoint and target pa-
rameter for the efficacy of omalizumab. The AFIRMM 
score represents the only published score in the literature 
to assess the severity of the disease in mastocytosis at the 
time of the study start [19, 20]. However, this score is very 
comprehensive and time-consuming as it includes a total 
of 38 items of potential symptoms in mastocytosis. One 
can consider that in some patients the AFIRMM score 
was not sensitive enough to detect smaller changes in the 
complaints. To simplify assessments, Broesby-Olsen et al. 
[14] used a physician global assessment symptom score 
for their cohort of 14 patients that focused on 5 symptom 
categories [6], and Siebenhaar et al. [21] developed a mas-
tocytosis activity score with only 3 domains (skin, gastro-
intestinal tract, and others). These simplified and alterna-
tive approaches could have enhanced differences between 
the study groups. 
After 6 months of therapy with omalizumab, the per 
protocol analysis in the omalizumab group showed a 
twice as high reduction in the AFIRMM score than in the 
placebo group. However, the low number of patients in-
cluded did not allow to reach differences that were at a 
significant level, even more so as it must be considered 
that the baseline values differed significantly in both 
groups. 
Thus, a tendency to improve mastocytosis symptoms 
was observed in the omalizumab treatment group, which 
corresponds to the effect described in the literature. The 
effect did not reach statistical significance, but this is most 
probably mainly due to the very low number of patients 
in this study who also showed a low disease severity [14].
The effect of omalizumab at the secondary endpoints 
was similar. The comparison of AFIRMM scores from 
baseline to follow-up showed large variations in the pla-
cebo group. In contrast, in the omalizumab group both 
the early follow-up (1 month after administration of the 
last study drug) and the late follow-up (4 months after 
administration of the last study drug) values showed an 
improvement of the AFIRMM scores. Differences were 
again not statistically significant.
Observational studies and case reports report a positive 
effect of omalizumab on the incidence of anaphylaxis [11, 
13, 20]. This effect was not confirmed in the present study 
because allergic or anaphylactic reactions occurred only 
twice in the small patient population, so that a more accu-
rate analysis between the 2 treatment groups was not pos-
sible. The low number of anaphylactic reactions again in-
dicates that less severely affected patients were included in 
this study than in comparable studies. To study this poten-
tial effect more closely, larger studies would be necessary.
Similarly, it was not possible to compare the use of 
mast cell-specific drugs in both groups, since only a few 
patients were using them – again confirming that the 
study included mainly less affected patients.
Looking at the course of the individual main com-
plaints indicated by the patients by using an analog scale, 
there was a slightly different pattern for the main com-
plaint “diarrhea” in 3 patients with omalizumab and 4 
patients with placebo. While the symptoms decreased 
with omalizumab, one saw very strong fluctuations in the 
placebo group. However, the significance of these values 
is again only very limited since only a few patient data are 
available. This observation corresponds to reports in the 
literature, which also indicate an amelioration of gastro-
intestinal complaints [11, 13].
For the main complaint asthenia, which was also often 
mentioned by our patients, the picture between the ver-
um and the placebo group is more heterogeneous, but 
here also only a few patients could be included.
On the other hand, there was no effect of omalizumab 
on the main complaint “pruritus,” which was recorded in 
all patients.
In order to make further statements about the main 
complaints, the gastrointestinal symptoms reported by 
the patients as single main complaints, as well as the com-
plaints from the area of allergy/flush as mentioned above, 
were summarized according to the grouping in the 
AFIRMM score and compared between the omalizumab 
and the verum group.
For the summarized gastrointestinal complaints, a to-
tal of 6 complaints in the verum and 11 complaints from 
the placebo group were observed. A similar picture was 
found for diarrhea alone with a decrease in the verum 
group and a very heterogeneous picture in the placebo 
group, but again without a significant difference. A cor-
responding picture was obtained in the summarized 
complaints from the allergy/flush group. Although there 
is a tendency for omalizumab to be effective in these com-
plaints, larger studies are necessary to allow more accu-
rate conclusions.
In terms of laboratory results, no correlation between 
total IgE and response to omalizumab could be investi-
gated. However, this may be due to the fact that only 1 
patient had a highly positive IgE (102 kU/L), whereas it 
was not over 36 kU/L in the other patients. Tryptase val-










































































There was a clear decrease in FcεRI expression after 
omalizumab treatment. However, a correlation with clin-
ical response to omalizumab could not be proven with 
certainty due to the low number of cases and the limited 
meaningfulness of the AFIRMM score in this study.
There was no significant difference between the verum 
and placebo groups regarding adverse events. Adverse 
events were mostly classified as mild, rarely as moderate, 
and for the most part unrelated to study medication. 
Omalizumab was generally very well tolerated. Adverse 
events, which were considered to be associated with the 
administration of the study drug, were hypertension in a 
patient with known arterial hypertension and hypercho-
lesterolemia, and injection site reactions and slight gen-
eral symptoms in another patient. This study in mastocy-
tosis thus confirms the good tolerability of omalizumab 
already described for use in allergic asthma. 
Our study has several limitations. First, all results of 
this study can only be evaluated to a limited extent due to 
the low number of patients. The small number of patients 
(5 verum/7 placebo group) resulted from the recruitment, 
which was complicated by the fact that many of the 67 
pre-screened mastocytosis patients had too few com-
plaints to participate in the study, whereas patients with 
too severe symptoms rejected study participation because 
of their concerns of being assigned to the placebo group. 
To account for the latter, we suggest a cross-over design 
for a future protocol in order to provide all study patients 
with the verum. Frequent study visits and/or duration of 
the study were other reasons not to participate. There-
fore, the value of the study results is only limited. 
Omalizumab is meanwhile approved for the treatment 
of urticaria in a dosage of 300 mg every 28 days. Perhaps 
this dosage would have shown more pronounced effects 
in this study. However, at the time of the study design and 
start of study, the results of the studies on the therapy of 
urticaria with omalizumab were not yet available, so that 
the dosages were adjusted to the recommendations for 
the treatment of bronchial asthma.
In conclusion, according to the collected data, some of 
the investigated parameters showed a tendency to improve 
the mastocytosis complaints under omalizumab. This was 
particularly true for the main complaints individually indi-
cated by the patients, especially gastrointestinal complaints 
and complaints like drug or food allergy or flush. A similar 
tendency was also shown for the summarized complaints in 
the relative AFIRMM score. These effects are in line with 
the effects of omalizumab in mastocytosis described in the 
literature and confirm the beneficial effect seen in other 
studies regarding the use of omalizumab in mastocytosis. 
Unfortunately, the observed effects were not signifi-
cant, which was mainly due to the low number of patients 
resulting from the difficult recruitment. However, the 
tendency for improvement, especially for gastrointestinal 
complaints, observed in this study indicates that the effect 
of omalizumab in mastocytosis is not only limited to di-
minishing allergic reactions. Therefore, further studies 
would be useful in order to verify these effects in a larger 
patient cohort.
Presumably due to the low number of participants, 
and possibly due to the fact that less severely affected pa-
tients were included, the effect of omalizumab on ana-
phylaxis in mastocytosis patients described in the litera-
ture could unfortunately not be further explored in this 
study. Again, larger studies would be necessary to inves-
tigate this effect.
Conclusion
Treatment of mastocytosis involves control of symp-
toms by blocking the action of mast cell mediators. Al-
though several new therapeutic strategies seem promis-
ing, including tyrosine kinase inhibitors for more severe 
forms of disease by targeting mast cell growth and its de-
velopment, therapy remains difficult, especially for pa-
tients with mainly allergic symptoms. In view of the het-
erogeneous nature of disease manifestations, the therapy 
should be individually adapted to each patient’s clinical 
presentation and prognosis. The role of omalizumab in 
an individualized treatment approach has yet to be deter-
mined, but seems to be beneficial from the results of our 
trial and also those of other small studies. Our results 
showed an improvement in mainly allergic symptoms, 
which should be confirmed by further studies with larger 
patient collectives.
Key Message
Omalizumab seems to have positive effects on mastocytosis 
symptoms in this clinical trial.
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